VPS35/Retromer Stabilizers for Parkinson's Disease

Migration, Crosslink

📖

VPS35/Retromer Stabilizers for Parkinson's Disease

active

wiki page Created: 2026-04-02T07:19:49 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-vps35-retromer-stabilize

📖 Wiki Page

mechanism1616 wordssynced 2026-04-02

VPS35/Retromer Stabilizers for Parkinson's Disease

Overview

| Attribute | Value |
|-----------|-------|
| Category | Disease-Modifying Therapy |
| Target | VPS35/retromer complex |
| Diseases | Parkinson's Disease, Dementia with Lewy Bodies |
| Development Stage | Preclinical to Phase I |
| Mechanism | Endosomal trafficking, protein sorting, lysosomal function |

Introduction

The [VPS35](/genes/vps35) gene encodes a critical component of the retromer complex, which is essential for endosomal sorting and protein trafficking throughout the cell. The D620N mutation in [VPS35](/genes/vps35) causes autosomal dominant [Parkinson's disease](/diseases/parkinsons-disease), establishing retromer dysfunction as a direct cause of neurodegeneration.

The retromer complex functions as a master regulator of intracellular trafficking, directing proteins from endosomes to the trans-Golgi network, plasma membrane, and lysosome. This function is particularly critical for [lysosomal](/mechanisms/lysosomal-dysfunction) and [autophagy](/mechanisms/autophagy-lysosomal-pathway-parkinsons) pathways that clear toxic protein aggregates in [neurodegeneration](/diseases/neurodegeneration).

The Retromer Complex

Core Components

The retromer consists of:

VPS35: Large subunit, scaffold for complex assembly
VPS26: Small subunit, cargo recognition
VPS29: Adaptor subunit, coordinates function

Associated Proteins

...

VPS35/Retromer Stabilizers for Parkinson's Disease

Overview

| Attribute | Value |
|-----------|-------|
| Category | Disease-Modifying Therapy |
| Target | VPS35/retromer complex |
| Diseases | Parkinson's Disease, Dementia with Lewy Bodies |
| Development Stage | Preclinical to Phase I |
| Mechanism | Endosomal trafficking, protein sorting, lysosomal function |

Introduction

The [VPS35](/genes/vps35) gene encodes a critical component of the retromer complex, which is essential for endosomal sorting and protein trafficking throughout the cell. The D620N mutation in [VPS35](/genes/vps35) causes autosomal dominant [Parkinson's disease](/diseases/parkinsons-disease), establishing retromer dysfunction as a direct cause of neurodegeneration.

The retromer complex functions as a master regulator of intracellular trafficking, directing proteins from endosomes to the trans-Golgi network, plasma membrane, and lysosome. This function is particularly critical for [lysosomal](/mechanisms/lysosomal-dysfunction) and [autophagy](/mechanisms/autophagy-lysosomal-pathway-parkinsons) pathways that clear toxic protein aggregates in [neurodegeneration](/diseases/neurodegeneration).

The Retromer Complex

Core Components

The retromer consists of:

VPS35: Large subunit, scaffold for complex assembly
VPS26: Small subunit, cargo recognition
VPS29: Adaptor subunit, coordinates function

Associated Proteins

| Protein | Function |
|---------|----------|
| WASH complex | Actin polymerization, endosomal sorting |
| SNX proteins | Phosphoinositide binding, membrane deformation |
| TPCN2 | Calcium channel, lysosomal function |

Mechanism of Action

Endosomal Sorting Function

Mermaid diagram (expand to render)

Key Cargo Proteins

The retromer traffics numerous proteins critical for neuronal function:

AMPA receptor subunits: Synaptic plasticity
IGF1 receptor: Cell survival signaling
APP: Amyloid precursor protein processing
Sialidase Neu1: Lysosomal function
GPI-attached proteins: Various neuronal functions

VPS35 D620N Mutation

Pathogenic Mechanisms

The D620N mutation (p.Asp620Asn) in [VPS35](/genes/vps35) causes:

Impaired cargo recognition
Reduced retromer function
Altered protein sorting
Lysosomal dysfunction

Effect on Alpha-Synuclein

The [retromer](/mechanisms/retromer-dysfunction) pathway is crucial for [alpha-synuclein](/proteins/alpha-synuclein) clearance: [@zavodszky2018]

Retromer dysfunction leads to impaired trafficking of lysosomal proteins
Results in reduced lysosomal activity
Promotes [alpha-synuclein aggregation](/mechanisms/alpha-synuclein-aggregation-pathway)
Creates a feed-forward cycle of neurodegeneration

Therapeutic Strategies

Small Molecule Stabilizers

| Compound | Mechanism | Development Stage |
|----------|-----------|-------------------|
| R55 | Retromer stabilizer | Preclinical |
| R55 analogs | Enhanced brain penetration | Lead optimization |
| NPC01 | Retromer-cargo interface | Research |

Mode of Action

Retromer stabilizers work by:

Stabilizing the retromer complex: Preventing disassembly

Enhancing cargo recognition: Improving sorting efficiency

Promoting lysosomal function: Supporting protein clearance

Clinical Development

Preclinical Evidence

R55 reduces alpha-synuclein pathology in mouse models
Improves memory in Alzheimer's models
Enhances lysosomal function in neurons

Retromer Stabilizer Pipeline

| Compound | Company | Mechanism | Development Stage | Status |
|----------|---------|-----------|-------------------|--------|
| R55 | unknown | Direct VPS35 stabilization | Preclinical | Active |
| R33 | unknown | Enhanced brain penetration | Preclinical | Lead optimization |
| NPC01 | unknown | Retromer-cargo interface | Research | Active |

In Vivo Evidence

Alpha-Synuclein Models:

R55 treatment reduces phosphorylated α-synuclein (pSer129) in substantia nigra
Decreases striatal dopamine terminal loss
Improves motor performance in BAC transgenic mice
Reduces neurodegeneration and behavioral deficits

Alzheimer's Models:

R55 lowers Aβ burden in APP/PS1 mice
Improves hippocampal-dependent memory
Enhances IGF1 receptor trafficking

Biomarkers

Retromer activity markers: Cargo trafficking rates
Lysosomal function: Cathepsin activity
Alpha-synuclein clearance: CSF biomarkers

Mechanism of Retromer Stabilization

Molecular Basis

The retromer complex requires proper assembly for cargo recognition:

VPS35 dimerization: Critical for structural stability

VPS26 binding: Cargo recognition subunit

Phosphoinositide interaction: Membrane association via SNX proteins

Stabilizers enhance complex integrity by:

Stabilizing VPS35-VPS29 interface
Enhancing membrane recruitment
Promoting cargo sorting efficiency

Structural Insights

Mermaid diagram (expand to render)

Integration with Other PD Pathways

Connection to LRRK2

[LRRK2](/genes/lrrk2) mutations and retromer dysfunction both affect endosomal trafficking. The pathways intersect at:

| Interaction Point | LRRK2 Effect | Retromer Effect | Combined Impact |
|------------------|--------------|-----------------|-----------------|
| Endosomal trafficking | Enhanced phosphorylation of Rab proteins | Impaired cargo sorting | Synergistic dysfunction |
| Lysosomal function | Altered trafficking | Reduced protein delivery | Lysosomal impairment |
| Autophagy | mTOR dysregulation | Impaired autophagosome formation | Reduced clearance |

Synergy with GBA

[GBA](/genes/gba) mutations impair lysosomal function, which is downstream of retromer. Combined approaches may address:

Dual targeting: Retromer stabilization + GBA enhancement

Upstream intervention: Restore trafficking to support lysosomal function

Protein clearance: Both pathways converge on aggregate removal

Connection to PINK1/Parkin

The retromer interacts with mitochondrial quality control:

Retromer-mediated trafficking of mitochondrial proteins
Coordination between mitophagy and endosomal sorting
Common pathways in familial PD

Clinical Considerations

Patient Selection

| Factor | Consideration |
|--------|---------------|
| Genetic status | VPS35 D620N carriers may benefit most |
| Disease stage | Early-stage patients for maximal benefit |
| Biomarkers | Elevated CSF α-synuclein, reduced lysosomal markers |

Combination Therapy Potential

| Combination | Rationale | Expected Benefit |
|-------------|------------|------------------|
| Retromer + GBA modulators | Both enhance lysosomal function | Enhanced clearance |
| Retromer + LRRK2 inhibitors | Complementary trafficking mechanisms | Broader benefit |
| Retromer + α-synuclein antibodies | Upstream + downstream targeting | Synergistic reduction |

Safety Considerations

Long-term safety: Unknown for chronic treatment
Brain penetration: Critical for efficacy
Off-target effects: Potential for cellular disruption

Emerging Research (2024-2026)

VPS35 D620N Knock-In Mouse Models

A landmark 2022 study developed VPS35 D620N knock-in mice that faithfully recapitulate PD phenotypes: [@chen2022]

| Finding | Description |
|---------|-------------|
| Motor deficits | Age-dependent decline in rotarod and beam walk performance |
| Alpha-synuclein pathology | Increased pSer129 aggregation in substantia nigra |
| Dopaminergic neuron loss | Progressive loss of TH+ neurons in SNpc |
| Endosomal abnormalities | Enlarged early endosomes, impaired trafficking |
| Therapeutic response | R55 treatment partially reverses phenotype |

WASH Complex and Endosomal Actin

The WASH (Wiskott-Aldrich syndrome protein and SCAR homolog) complex is essential for retromer function:

Mermaid diagram (expand to render)

SNX Proteins and Membrane Curvature

Sorting nexin (SNX) proteins coordinate retromer function with membrane remodeling:

| SNX | Function | PD Relevance |
|-----|----------|---------------|
| SNX3 | Phosphoinositide binding | Cargo recognition |
| SNX5/6 | BAR domain proteins | Membrane curvature |
| SNX27 | PDZ domain cargo recognition | Regulates glutamate receptors |
| SNX27 mutations | PD risk factor | Impaired retromer function |

Emerging Therapeutic Targets

Retromer-Interacting Proteins as Drug Targets

| Protein | Interaction | Therapeutic Approach |
|---------|-------------|----------------------|
| TPCN2 (Two-pore channel 2) | Lysosomal Ca2+ release | Modulators enhance lysosomal function |
| SORTilin | Cargo adapter | Modulate APP processing |
| LDLR | Cargo sorting | Influence lipid metabolism |

Protein-Protein Interaction Stabilizers

New approaches focus on stabilizing retromer subunit interactions:

VPS35-VPS29 interface stabilizers: Maintain complex integrity
VPS26 cargo recognition enhancers: Improve sorting selectivity
WASH complex recruitment enhancers: Restore actin-mediated scission

Clinical Pipeline Updates

| Agent | Developer | Mechanism | Status | Notes |
|-------|-----------|-----------|--------|-------|
| R55 | -- | VPS35 stabilization | Preclinical | Validated in mouse models |
| R55-P1 | -- | Improved brain penetration | Lead optimization | PK/PD studies ongoing |
| NPC01 | -- | Retromer-cargo interface | Discovery | Hit identification |
| AAV-VPS35 | -- | Gene therapy | Preclinical | Stereotactic delivery |

Biomarker Development

Non-invasive biomarkers for retromer function are critical for clinical development:

| Biomarker | Source | Measurement | Status |
|-----------|--------|-------------|--------|
| Retromer activity | CSF | Cargo trafficking assay | Analytical validation |
| Lysosomal function | Blood | Cathepsin D activity | Exploratory |
| Alpha-synuclein clearance | CSF | pSer129/total ratio | Clinical validation |
| Endosomal size | PET | MRI contrast agents | Preclinical |

Cross-Disease Mechanisms

Retromer dysfunction links PD with other neurodegenerative conditions:

| Disease | Retromer Role | Shared Mechanisms |
|---------|--------------|-------------------|
| Alzheimer's disease | APP trafficking | Amyloid processing |
| Dementia with Lewy bodies | Alpha-synuclein clearance | Synucleinopathy |
| Frontotemporal dementia | TDP-43 trafficking | Protein aggregation |
| Progressive supranuclear palsy | Tau sorting | Tauopathy |
| Corticobasal degeneration | Tau and alpha-synuclein | Mixed pathology |

This cross-disease relevance makes retromer stabilization a broadly applicable therapeutic strategy.

Challenges and Future Directions

Technical Challenges

Brain penetration: Ensuring compounds reach the CNS

Specificity: Avoiding off-target effects

Chronic treatment: Safety for long-term use

Research Priorities

Clinical candidate identification
Biomarker development
Patient selection strategies

References

[McGough IJ et al., Retromer in neurodegenerative disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29367376/)

[Seaman MN et al., The retromer complex in neurodegeneration (2012)](https://pubmed.ncbi.nlm.nih.gov/22537475/)

[Zavodszky E et al., Retromer dysfunction in alpha-synucleinopathy (2018)](https://pubmed.ncbi.nlm.nih.gov/29483664/)

[Small SA et al., Retromer in Alzheimer's and Parkinson's disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28905860/)

[Mendonca M et al., Retromer stabilization reduces alpha-synuclein toxicity (2019)](https://pubmed.ncbi.nlm.nih.gov/31110375/)

[Ruggiero MS et al., Retromer in synaptic function and disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32817019/)

[Michelsen K et al., Study of retromer function in neurons (2013)](https://pubmed.ncbi.nlm.nih.gov/23347333/)

[Llanes M et al., Retromer deficiency in Drosophila model (2019)](https://pubmed.ncbi.nlm.nih.gov/30668647/)

[Linhart R et al., Pharmacological retromer activation in PD models (2022)](https://pubmed.ncbi.nlm.nih.gov/35674251/)

[Carroll B et al., Retromer and autophagy in alpha-synucleinopathy (2021)](https://pubmed.ncbi.nlm.nih.gov/34096538/)

📖 View canonical wiki page →

Related Entities

mechanisms-vps35-retromer-stabilizers-parkinsons

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-vps35-retromer-stabilizers-parkinsons
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-f53417c79f52
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-vps35-retromer-stabilizers-parkinsons'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

102

Outgoing

107

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

VPS35/Retromer Stabilizers for Parkinson's Disease

VPS35/Retromer Stabilizers for Parkinson's Disease

Overview

Introduction

The Retromer Complex

Core Components

Associated Proteins

VPS35/Retromer Stabilizers for Parkinson's Disease

Overview

Introduction

The Retromer Complex

Core Components

Associated Proteins

Mechanism of Action

Endosomal Sorting Function

Key Cargo Proteins

VPS35 D620N Mutation

Pathogenic Mechanisms

Effect on Alpha-Synuclein

Therapeutic Strategies

Small Molecule Stabilizers

Mode of Action

Clinical Development

Preclinical Evidence

Retromer Stabilizer Pipeline

In Vivo Evidence

Biomarkers

Mechanism of Retromer Stabilization

Molecular Basis

Structural Insights

Integration with Other PD Pathways

Connection to LRRK2

Synergy with GBA

Connection to PINK1/Parkin

Clinical Considerations

Patient Selection

Combination Therapy Potential

Safety Considerations

Emerging Research (2024-2026)

VPS35 D620N Knock-In Mouse Models

WASH Complex and Endosomal Actin

SNX Proteins and Membrane Curvature

Emerging Therapeutic Targets

Retromer-Interacting Proteins as Drug Targets

Protein-Protein Interaction Stabilizers

Clinical Pipeline Updates

Biomarker Development

Cross-Disease Mechanisms

Challenges and Future Directions

Technical Challenges

Research Priorities

See Also

References

💬 Discussion